HomeCompareNOVN vs MRK

NOVN vs MRK: Dividend Comparison 2026

NOVN yields 2125.40% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NOVN wins by $17531898098.58M in total portfolio value
10 years
NOVN
NOVN
● Live price
2125.40%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17531898098.63M
Annual income
$16,046,703,901,914,954.00
Full NOVN calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — NOVN vs MRK

📍 NOVN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNOVNMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NOVN + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NOVN pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NOVN
Annual income on $10K today (after 15% tax)
$180,658.87/yr
After 10yr DRIP, annual income (after tax)
$13,639,698,316,627,710.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, NOVN beats the other by $13,639,698,316,619,382.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NOVN + MRK for your $10,000?

NOVN: 50%MRK: 50%
100% MRK50/50100% NOVN
Portfolio after 10yr
$8765949049.35M
Annual income
$8,023,351,950,962,376.00/yr
Blended yield
91.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NOVN
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
Altman Z
-6.8
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NOVN buys
0
MRK buys
0
No recent congressional trades found for NOVN or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNOVNMRK
Forward yield2125.40%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$17531898098.63M$56.8K
Annual income after 10y$16,046,703,901,914,954.00$9,798.13
Total dividends collected$17426965851.86M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: NOVN vs MRK ($10,000, DRIP)

YearNOVN PortfolioNOVN Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$223,240$212,539.85$11,206$366.19+$212.0KNOVN
2$4,673,200$4,434,333.16$12,650$502.35+$4.66MNOVN
3$91,753,856$86,753,532.14$14,407$694.19+$91.74MNOVN
4$1,690,067,758$1,591,891,132.54$16,585$967.82+$1690.05MNOVN
5$29,212,083,466$27,403,710,964.97$19,342$1,363.89+$29212.06MNOVN
6$473,930,931,126$442,674,001,816.98$22,913$1,947.19+$473930.91MNOVN
7$7,219,118,648,525$6,712,012,552,220.43$27,662$2,823.89+$7219118.62MNOVN
8$103,276,088,728,702$95,551,631,774,779.60$34,159$4,173.35+$103276088.69MNOVN
9$1,388,031,959,551,211$1,277,526,544,611,500.20$43,337$6,308.80+$1388031959.51MNOVN
10$17,531,898,098,634,750$16,046,703,901,914,954.00$56,776$9,798.13+$17531898098.58MNOVN

NOVN vs MRK: Complete Analysis 2026

NOVNStock

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Full NOVN Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NOVN vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NOVN vs SCHDNOVN vs JEPINOVN vs ONOVN vs KONOVN vs MAINNOVN vs JNJNOVN vs ABBVNOVN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.